Bone metastasis market forecast to hit $67.4 billion by 2035

Market Research Future projects the global bone metastasis market will grow from $25.11 billion in 2026 to $67.40 billion by 2035, driven by rising cancer incidence, wider use of radiopharmaceuticals and reimbursement tied to skeletal-event prevention. The outlook points to faster adoption in North America and Asia-Pacific as treatment shifts toward earlier, more personalized care. Why it matters: - The bone metastasis market is being shaped by higher cancer survival, more patients living long enough to need ongoing skeletal metastasis therapy, and payer pressure to prevent costly skeletal-related events. - The shift away from reactive treatment toward preventive and precision oncology could expand access to bone-modifying agents and radiopharmaceuticals through 2035. What happened: - Market Research Future projects the global bone metastasis market will rise from $25.11 billion in 2026 to $67.40 billion by 2035. - The forecast implies an 11.6% compound annual growth rate for 2026-2035. - The market base was estimated at $22.50 billion in 2025. - The report ties growth to rising global cancer incidence, alpha-emitting radiopharmaceutical expansion and value-based oncology reimbursement. The details: - The WHO Global Cancer Observatory estimates combined breast, prostate and lung cancer diagnoses will exceed 8.5 million annually by 2030, up from 6.8 million in 2022. - Roughly 65%-75% of advanced breast and prostate cancer patients develop bone lesions, expanding demand for osteolytic metastasis drugs and bone-modifying agents. - Extended survival in metastatic cancers is increasing the number of patients who need long-term skeletal metastasis therapy. - AI-enhanced PET/CT and SPECT/CT platforms are replacing older whole-body bone scans for earlier detection. - Bayer’s radium-223 established targeted alpha therapy in castration-resistant prostate cancer. - The pipeline now includes actinium-225 and lead-212 conjugates in Phase II/III evaluation. - The U.S. Department of Energy committed $220 million to domestic isotope production through its Isotope Program. - The European Medicines Agency granted conditional approvals in 2024 that shortened time-to-market by about 14 months for two alpha-emitter candidates. - CMS’s Oncology Care Model and the Enhancing Oncology Model tie provider reimbursement to skeletal-related-event reduction metrics. - ESCEO data show preventing one skeletal-related event saves payers about $60,000-$70,000 per patient. Between the lines: - The market is moving from a palliative-care framing to a prevention and precision-therapy model. - Pooled procurement and reference pricing are likely to keep pricing pressure on manufacturers even as access expands. - The strongest growth may come from products and workflows that combine diagnosis and treatment, especially theranostic radiopharmaceutical platforms. - Patent expirations and biosimilar entry could lower drug prices, but higher patient volumes may offset some of the revenue pressure. What’s next: - By 2030, an estimated 40% of newly diagnosed metastatic prostate cancer patients are expected to undergo PSMA-PET staging followed by matched radioligand skeletal metastasis therapy. - Novartis invested more than $2.1 billion in radiopharmaceutical infrastructure from 2022 to 2025, signaling continued scale-up in the category. - Denosumab patent expirations expected in 2025-2027 could trigger biosimilar competition and reduce costs by 30%-45% in key markets. - AI-integrated clinical decision support is expected to guide treatment sequencing by 2028-2030, with ASCO and ESMO developing related frameworks. The bottom line: - Bone metastasis care is shifting toward earlier detection, targeted radiopharmaceuticals and reimbursement models that reward prevention, setting up a sizable market expansion through 2035.